Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the role of vitamin D in regulating immune responses related to autoimmune diseases like alopecia areata, but it presents no new clinical findings.

This study reported that platelet-rich plasma therapy showed a positive response in improving hair density and thickness among patients with androgenic alopecia.

This study reported a higher prevalence of androgenetic alopecia in male respondents compared to female respondents in different regions of Saudi Arabia.

Loose anagen hair syndrome in children may improve with age, but treatment results vary.

This systematic review of pulse corticosteroid therapy for alopecia areata found relatively low complete response rates, but responders experienced low relapse rates, indicating potential benefits for patients with favorable prognostic factors.

This article reports a case of frontal fibrosing alopecia in its early inflammatory stage that responded positively to intralesional steroid treatment.

This study reported that both 5% topical and oral minoxidil achieved an 82% hair regrowth response rate in alopecia areata patients, but 5% topical minoxidil was more effective than lower concentrations.

This case report describes a patient with alopecia universalis who had an excellent and persistent response to oral tofacitinib treatment after one year.

This study found that latanoprost may be effective for treating eyelash alopecia areata, achieving cosmetically acceptable regrowth in 45% of patients.

This article discusses treatments for male pattern alopecia, noting variable response rates, but reports no new clinical results.

This study found that baricitinib significantly reduced alopecia severity in JAK inhibitor-naïve patients compared to those previously treated with tofacitinib, indicating that switching JAK inhibitors can be safe and may be beneficial for selected patients with partial prior responses.

This article summarizes expert opinions from Indian dermatologists on managing androgenetic alopecia and telogen effluvium, emphasizing varied treatments based on individual patterns and responses.

This study found that individuals with androgenic alopecia have an increased number of thin hairs (less than 40 microns in diameter) per cm², which may affect their clinical appearance.

In this study, pioglitazone treatment in patients with lichen planopilaris showed limited success, with significant improvement seen in only a minority of cases.

This study reviewed the evidence on minoxidil's effectiveness for androgenetic alopecia, finding that 5% topical minoxidil is the most effective monotherapy for men, while 2% is similarly effective for women. Genetic markers can predict response, and new formulations like foam and gel improve tolerability.

In this case report, off-label onabotulinumtoxin-A was successfully used to treat trichodynia, a painful scalp sensation associated with hair loss, in a patient unresponsive to conventional therapies.

In this study conducted at Al-Azhar University Hospital, 60% of patients with localized alopecia areata responded to treatment with autologous platelet-rich plasma, with 89% of responders showing substantial improvement, suggesting PRP as an effective treatment option for this condition.

In this study, conducted through a survey in Ukraine, researchers found that 48.7% of men believe androgenic alopecia negatively affects their emotional state and quality of life, with approximately 90% expressing the need for more effective treatments on the market.

This study found that platelet-rich plasma significantly increased hair count, density, and the percentage of anagen hairs in patients with androgenetic alopecia, but these improvements did not correlate with platelet or growth factor levels.

This manuscript reviews the latest understanding of alopecia areata's pathogenesis, highlighting the roles of genetic, immunological, and environmental factors, with a focus on immune responses involving IFN-γ and cytotoxic CD8+ T-cells as key contributors to hair follicle inflammation and function disruption without follicle destruction.

This study observed that in vitro treatment of male frontotemporal scalp hair follicles with 17-β-estradiol stimulated hair shaft generation and hair matrix keratinocyte proliferation, suggesting potential anagen-prolonging effects.

In this study, bimatoprost solution showed better results than corticosteroid in terms of rapidity, percentage of hair regrowth, and side effects for treating scalp alopecia areata.

This study discusses the role of CD8+ T-cell and interferon γ signaling in vitiligo's pathogenesis and notes that JAK inhibitors, which are FDA-approved for other autoimmune diseases, may offer a potential treatment path by blocking this pathway.

This study found that subcutaneous testosterone therapy improved scalp hair growth in a majority of androgen-deficient women who previously reported hair thinning and did not report hair loss as a side effect.

This study reports cases of histopathologically proven cutaneous lupus erythematosus manifesting as frontal fibrosing alopecia, with improvement following treatment with oral hydroxychloroquine and/or intralesional triamcinolone acetonide.

This study found that hair mass index can effectively link hair productivity with clinical scalp coverage perception, suggesting its potential usefulness in diagnosing hair loss patterns and responses to treatment.

This source highlights the importance of a multidisciplinary approach, involving medical, mental health, and trichology professionals along with peer support facilitators, in promoting psychological well-being for individuals with alopecia areata.

This study found that platelet-rich plasma therapy significantly improved hair density, diameter, and reduced inflammation in androgenetic alopecia patients compared to placebo, though individual responses varied.

This study found that dermatologists in an urban academic setting most frequently use topical corticosteroids, intralesional corticosteroids, and topical minoxidil for treating central centrifugal cicatricial alopecia, aligning with current literature recommendations on reducing inflammation.

This article reviews treatment options for Alopecia Areata, concluding that topical corticosteroids are effective for mild cases, while systemic therapies are advised for moderate to severe cases.